Payment overview · 2025
General Payments
$25,267.55
173 reported records · 34 companies
Healthcare provider profile · identity verified
Adrian Antonio Santamaria, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · TOMBALL, TX · NPI 1346444932
Verified facts
What the public records show
CMS Open Payments records show Adrian Antonio Santamaria, MD received $25,267.55 in general payments during 2025 across 173 reported records.
Inspire Medical Systems, Inc. accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C, Lumryz, Nurtec Odt, Wakix, Xywav.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rytary by this doctor in 2024.
Avadel CNS Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMRYZ as an associated drug or biological on 11767 records involving 3739 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lumryz by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gamunex-C by this doctor in 2024.
HARMONY BIOSCIENCES LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAKIX as an associated drug or biological on 20652 records involving 6156 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wakix by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Xywav by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $8,519.08 | 33.7% | 55 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $8,055.60 | 31.9% | 16 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $6,748.34 | 26.7% | 12 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $329.46 | 1.3% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $178.10 | 0.7% | 13 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $136.32 | 0.5% | 6 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$135.61 | 0.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $114.25 | 0.5% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $102.35 | 0.4% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $86.77 | 0.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.49 | 0.3% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $68.00 | 0.3% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $60.05 | 0.2% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $59.60 | 0.2% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.94 | 0.2% | 7 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $47.17 | 0.2% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $46.40 | 0.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $41.48 | 0.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.82 | 0.1% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.07 | 0.1% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $30.94 | 0.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $30.32 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.10 | 0.1% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $25.79 | 0.1% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $24.81 | 0.1% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $24.79 | 0.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.59 | 0.1% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $23.10 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.40 | 0.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.94 | 0.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.27 | 0.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.78 | 0.1% | 1 | 2025 |
| ZOLL Respicardia, Inc. | Unresolved — no canonical attribution shown | $16.09 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.73 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,275.00 | 5 |
| Consulting Fee | $9,095.00 | 3 |
| Food and Beverage | $3,606.67 | 145 |
| Honoraria | $2,000.00 | 1 |
| Travel and Lodging | $1,184.93 | 17 |
| Education | $105.95 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $8,519.08 | 55 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $8,055.60 | 16 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $6,748.34 | 12 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $329.46 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $178.10 | 13 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $136.32 | 6 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $102.35 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $91.05 | 7 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $86.77 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $81.49 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.49 | 3 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $68.39 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $68.00 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $60.05 | 3 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $55.94 | 7 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $47.17 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $46.40 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $41.48 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $38.07 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $31.85 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $30.32 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| Home PI Undivided Normalized: home pi undivided |
Device | Philips North America LLC | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| remede System Normalized: remede system |
Device | ZOLL Respicardia, Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LUMRYZ lumryz |
2025 | Lumryz | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| WAKIX wakix |
2025 | Wakix | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYWAV xywav |
2025 | Xywav | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Avadel CNS Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | LUMRYZ open payments reported associated product |
CMS Open Payments — General Payments 11767 supporting records · 3739 recipient NPIs · example record 1208530440 |
Lumryz · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| HARMONY BIOSCIENCES LLC Exact reporting entity; no affiliate inference |
2025 | WAKIX open payments reported associated product |
CMS Open Payments — General Payments 20652 supporting records · 6156 recipient NPIs · example record 1222387076 |
Wakix · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 246 | 75 |
| Memantine Hcl | Memantine Hcl | 216 | 61 |
| Gabapentin | Gabapentin | 181 | 68 |
| Levetiracetam | Levetiracetam | 153 | 46 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 150 | 46 |
| Sertraline Hcl | Sertraline Hcl | 127 | 34 |
| Clonazepam | Clonazepam | 110 | 25 |
| Donepezil Hcl | Donepezil Hcl | 81 | 33 |
| Lacosamide | Lacosamide | 73 | 11 |
| Xywav | Sodium,calcium,mag,pot Oxybate | 70 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 21 |
| Propranolol Hcl | Propranolol Hcl | 56 | 18 |
| Rivastigmine | Rivastigmine Tartrate | 48 | 16 |
| Lamotrigine | Lamotrigine | 40 | 13 |
| Topiramate | Topiramate | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Eszopiclone | Eszopiclone | 35 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Carbamazepine Er | Carbamazepine | 34 | suppressed |
| Armodafinil | Armodafinil | 33 | suppressed |
| Zonisamide | Zonisamide | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | 12 |
| Sodium Oxybate | Sodium Oxybate | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 26 | suppressed |
| Rytary | Carbidopa/Levodopa | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 22 | suppressed |
| Lumryz | Sodium Oxybate | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Neupro | Rotigotine | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Wakix | Pitolisant Hcl | 15 | suppressed |
| Copaxone | Glatiramer Acetate | 14 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fycompa | Perampanel | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
| Fingolimod | Fingolimod Hcl | 11 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25,267.55 · 173 records | Inspire Medical Systems, Inc. | AMYVID, AUSTEDO XR, BRIUMVI, CREXONT, ETERNA, Fintepla, Gamunex-C, HYQVIA, Home PI Undivided, INFINITY, INGREZZA, INSPIRE, KESIMPTA, KEVEYIS, KISUNLA, LUMRYZ, LUNA, Leqembi, Motpoly XR, NEURACEQ, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, PROCLAIM, QULIPTA, REXULTI, Rystiggo, Sunosi, TRUDHESA, UBRELVY, ULTOMIRIS, UPLIZNA, VYEPTI, VYVGART HYTRULO, WAKIX, XYWAV, ZAVZPRET, ZEPOSIA, remede System | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error